Search results for " Combination"

showing 10 items of 923 documents

TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1.

2011

Summary.  The triglycerides × glucose (TyG) index is a recently proposed surrogate marker of insulin resistance (IR), calculated from fasting plasma triglyceride and glucose concentrations. We tested the host and viral factors associated with Tyg and homeostasis model assessment (HOMA) scores, comparing their associations with histological features and with sustained virological response (SVR) in patients with genotype 1 chronic hepatitis C(G1CHC). Three hundred and forty consecutive patients with G1CHC were considered. All had a liver biopsy scored by one pathologist for staging and grading (Scheuer), and graded for steatosis, which was considered moderate–severe if ≥30%. Anthropometric an…

CHRONIC HEPATITIS CAdultBlood GlucoseMalemedicine.medical_specialtyAlpha interferonHepacivirusGastroenterologyAntiviral AgentsGLUCOSEBody Mass IndexPolyethylene GlycolsInsulin resistanceVirologyInternal medicineRibavirinmedicineHomeostasisHumansTriglyceridesAgedHepatologymedicine.diagnostic_testbusiness.industryFatty liverInterferon-alphaHepatitis CHepatitis C ChronicMiddle AgedViral Loadmedicine.diseaseRecombinant ProteinsFatty LiverInfectious DiseasesEndocrinologyTreatment OutcomeLiver biopsySUSTAINED VIROLOGICAL RESPONSERNA ViralDrug Therapy CombinationFemaleSteatosisInsulin ResistancebusinessViral loadBody mass indexJournal of viral hepatitis
researchProduct

Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers

2015

Introduction: The efficacy and safety of a new once-daily (QD) fixed-dose combination (FDC) with tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β 2 -agonist, was established for the treatment of COPD in the TONADO studies (NCT01431274; NCT01431287). This analysis evaluates the efficacy of the FDC in a subpopulation of patients receiving β-blockers (BBs) in these studies. Methods: Two replicate, randomised, double-blind, parallel-group, 52-week, Phase III trials assessed the efficacy and safety of T+O FDC (2.5/5 μg; 5/5 μg; Respimat ® inhaler) QD compared to the monocomponents. Key primary end point data for the combined analysis of the replicate trial…

COPDmedicine.medical_specialtyRespimatbusiness.industryInhalerOlodaterolFixed-dose combinationMuscarinic antagonistmedicine.diseasechemistry.chemical_compoundchemistryInternal medicinemedicinePhysical therapyClinical endpointIn patientbusinessmedicine.drug5.1 Airway Pharmacology and Treatment
researchProduct

Implantation of silicon dioxide-based nanocrystalline hydroxyapatite and pure phase beta-tricalciumphosphate bone substitute granules in caprine musc…

2012

Abstract Background Osteoinductive bone substitutes are defined by their ability to induce new bone formation even at heterotopic implantation sites. The present study was designed to analyze the potential osteoinductivity of two different bone substitute materials in caprine muscle tissue. Materials and methods One gram each of either a porous beta-tricalcium phosphate (β-TCP) or an hydroxyapatite/silicon dioxide (HA/SiO2)-based nanocrystalline bone substitute material was implanted in several muscle pouches of goats. The biomaterials were explanted at 29, 91 and 181 days after implantation. Conventional histology and special histochemical stains were performed to detect osteoblast precurs…

Calcium Phosphateslcsh:Specialties of internal medicineClinical Neurology610 MedizinBiocompatible MaterialsCerasorbHydroxyapatiteOsteogenesislcsh:RC581-951610 Medical sciencesAnimalsSolid-Phase Synthesis TechniquesDentistry(all)GoatsMusclesResearchNanocrystallineSilicon DioxideEctopic bone formationDrug CombinationsDurapatiteß-tricalciumphosphateOtorhinolaryngologyOsteoinductionBone SubstitutesModels AnimalNanoparticlesFemaleNanoBone
researchProduct

Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis

2012

The present study is designed to assess if exosomes released from Chronic Myelogenous Leukemia (CML) cells may modulate angiogenesis. We have isolated and characterized the exosomes generated from LAMA84 CML cells and demonstrated that addition of exosomes to human vascular endothelial cells (HUVEC) induces an increase of both ICAM-1 and VCAM-1 cell adhesion molecules and interleukin-8 expression. The stimulation of cell-cell adhesion molecules was paralleled by a dose-dependent increase of adhesion of CML cells to a HUVEC monolayer. We further showed that the treatment with exosomes from CML cells caused an increase in endothelial cell motility accompanied by a loss of VE-cadherin and β-ca…

Cancer ResearchAngiogenesisVascular Cell Adhesion Molecule-1BiologyExosomesArticleExosomes Chronic Myelogenous Leukemia Cells Endothelial cells Tumor MicroenvironmentMiceAntigens CDCell Movementhemic and lymphatic diseasesCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositivemedicineCell AdhesionHuman Umbilical Vein Endothelial CellsTumor MicroenvironmentAnimalsHumansCell adhesionbeta CateninMatrigelTumor microenvironmentNeovascularization PathologicCell adhesion moleculeInterleukin-8medicine.diseaseCadherinsIntercellular Adhesion Molecule-1MicrovesiclesCell biologyEndothelial stem cellDrug CombinationsOncologyGene Expression RegulationCancer researchProteoglycansCollagenLamininChronic myelogenous leukemia
researchProduct

A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceram…

2014

AbstractGlioblastomas (GBMs) are very aggressive tumors with low chemosensitivity. The DNA-alkylating agent temozolomide (TMZ) is currently the most efficient chemotoxic drug for GBM therapy; however, many patients develop resistance to TMZ. Combining TMZ with another agent could present an improved treatment option if it could overcome TMZ resistance and avoid side effects. Sphingosine kinase inhibitors (SKIs) have emerged as anticancer agents. Sphingosine kinases are often overexpressed in tumors where their activity of phosphorylating sphingosine (Sph) contributes to tumor growth and migration. They control the levels of the pro-apoptotic ceramide (Cer) and Sph and of the pro-survival sp…

Cancer ResearchCeramideProgrammed cell deathImmunologySphingosine kinaseAntineoplastic AgentsApoptosisBiologyCeramidesCellular and Molecular Neurosciencechemistry.chemical_compoundSphingosineCell Line TumorAutophagyTemozolomideHumansEnzyme InhibitorsCytotoxicitySphingosineCell DeathKinaseBrain NeoplasmsAutophagyCell BiologyEndoplasmic Reticulum StressCell biologyDacarbazinePhosphotransferases (Alcohol Group Acceptor)chemistryApoptosisDrug Resistance NeoplasmCancer researchDrug Therapy CombinationOriginal ArticleGlioblastomaCell deathdisease
researchProduct

GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer

2021

Pancreatic cancer is an aggressive malignancy with increasing incidence and poor prognosis due to its late diagnosis and intrinsic chemoresistance. Most pancreatic cancer patients present with locally advanced or metastatic disease characterized by inherent resistance to chemotherapy. These features pose a series of therapeutic challenges and new targets are urgently needed. Glycogen synthase kinase 3 beta (GSK3β) is a conserved serine/threonine kinase, which regulates key cellular processes including cell proliferation, DNA repair, cell cycle progression, signaling and metabolic pathways. GSK3β is implicated in non-malignant and malignant diseases including inflammation, neurodegenerative …

Cancer ResearchDNA repairDruggabilityDiseaseMalignancyPancreatic cancerHumansMedicinePharmacology (medical)GSK3BCell ProliferationPharmacologyGlycogen Synthase Kinase 3 betabusiness.industryKinaseGSK3βCancerTumor chromatin profilingOncogenesPancreatic cancermedicine.diseaseAnticancer drug combinationsPancreatic NeoplasmsInfectious DiseasesOncologyDrug Resistance NeoplasmCancer researchbusinessChemoresistanceDrug Resistance Updates
researchProduct

Sodium phenylbutyrate induces apoptosis in human retinoblastoma Y79 cells: The effect of combined treatment with the topoisomerase I-inhibitor topote…

2001

Our results demonstrate that sodium phenylbutyrate, a compound with a low degree of toxicity, exerted a cytotoxic effect on human retinoblastoma Y79 cells in a time- and dose-dependent manner. Treatment of Y79 cells for 72 h with phenylbutyrate reduced cell viability by 63% at 2 mM and 90% at 4 mM. Cell death caused by phenylbutyrate exhibited the typical features of apoptosis, as shown by light and fluorescent microscopy. Western blot analysis demonstrated that exposure of Y79 cells to phenylbutyrate decreased the level of the antiapoptotic factor Bcl-2 and induced the activation of caspase-3, a key enzyme in the execution phase of apoptosis. Moreover, treatment with phenylbutyrate markedl…

Cancer ResearchProgrammed cell deathCell SurvivalBlotting WesternApoptosisPhenylbutyrateHistonesSettore BIO/10 - BiochimicamedicineTumor Cells CulturedHumansretinoblastoma apoptosis sodium phenylbutirateViability assayEnzyme InhibitorsbiologyCaspase 3TopoisomeraseRetinoblastomaSodium phenylbutyrateAcetylationDrug SynergismCell cyclePhenylbutyrateseye diseasesEnzyme ActivationOncologyProto-Oncogene Proteins c-bcl-2ApoptosisCaspasesbiology.proteinCancer researchTopotecanDrug Therapy CombinationTopoisomerase I InhibitorsTumor Suppressor Protein p53Topotecanmedicine.drug
researchProduct

Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a pr…

2013

PURPOSE To assess the efficacy of gonadotropin-releasing hormone agonist (GnRHa) in preventing chemotherapy-induced ovarian failure in patients treated for Hodgkin or non-Hodgkin lymphoma within the setting of a multicenter, randomized, prospective trial. PATIENTS AND METHODS Patients age 18 to 45 years were randomly assigned to receive either the GnRHa triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) concomitantly with alkylating agents containing chemotherapy. The primary end point was the premature ovarian failure (POF) rate (follicle-stimulating hormone [FSH] ≥ 40 IU/L) after 1 year of follow-up. Results Eighty-four of 129 randomly assigned patients …

Cancer ResearchTime FactorsLymphomamedicine.medical_treatmentGonadotropin-Releasing Hormone -- agonistsPrimary Ovarian InsufficiencyTriptorelin Pamoate -- therapeutic uselaw.inventionGonadotropin-Releasing HormoneGynécologieRandomized controlled triallawAntineoplastic Combined Chemotherapy ProtocolsClinical endpointBiological Markers -- bloodNorethindrone -- therapeutic useProspective StudiesTreatment FailureProspective cohort studyTriptorelin PamoateEstradiolLymphoma Non-HodgkinLymphoma -- drug therapyMiddle AgedTriptorelinHodgkin DiseasePremature ovarian failureLuteolytic AgentsOncologyHodgkin Disease -- drug therapyDrug Therapy CombinationFemaleEstradiol -- bloodmedicine.drugAdultAntineoplastic Combined Chemotherapy Protocols -- administration & dosage -- adverse effectsmedicine.medical_specialtyNorethisteronemedicine.drug_classUrologyFollicle Stimulating Hormone -- bloodGonadotropin-releasing hormone agonistmedicineHumansGynecologyChemotherapybusiness.industrymedicine.diseaseLuteolytic Agents -- therapeutic useCancérologieLymphoma Non-Hodgkin -- drug therapyPremenopausePrimary Ovarian Insufficiency -- blood -- chemically induced -- prevention & controlFollicle Stimulating HormoneNorethindronebusinessBiomarkersFollow-Up Studies
researchProduct

Analysis of Antiproliferative and Chemosensitizing Effects of Sunitinib on Human Esophagogastric Cancer Cells: Synergistic Interaction With Vandetani…

2009

The receptor tyrosine kinases (RTKs), epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor 1-3 (VEGFR1-3), are frequently expressed in gastric cancer and are putative therapeutic targets in this disease. We have investigated the anti-proliferative and chemosensitizing properties of the multitargeted small-molecule RTK inhibitors sunitinib and vandetanib in a panel of 4 human gastric and esophageal cancer cell lines. In the 1st instance, the expression of potential targets of these small-molecule inhibitors was examined by reverse transcriptase-polymerase chain reaction, western blotting, and flow cytometry. EGFR mRNA and protein was detected in all cases, …

Cancer ResearchUmbilical VeinsIndolesEsophageal NeoplasmsApoptosisVandetanibTyrosine-kinase inhibitorReceptor tyrosine kinasechemistry.chemical_compoundPiperidinesSunitinibMedicineDrug InteractionsEpidermal growth factor receptorPhosphorylationCells CulturedbiologySunitinibReverse Transcriptase Polymerase Chain ReactionDrug SynergismFlow CytometryErbB ReceptorsOncologyPhosphorylationDrug Therapy Combinationmedicine.drugSignal Transductionmedicine.medical_specialtymedicine.drug_classBlotting WesternAntineoplastic AgentsStomach NeoplasmsInternal medicineHumansPyrrolesPropidium iodideRNA MessengerProtein Kinase InhibitorsCell ProliferationVascular Endothelial Growth Factor Receptor-1business.industryCancermedicine.diseaseVascular Endothelial Growth Factor Receptor-3Vascular Endothelial Growth Factor Receptor-2EndocrinologychemistryCancer researchbiology.proteinQuinazolinesEndothelium VascularbusinessProto-Oncogene Proteins c-akt
researchProduct

Extensive phytocannabinoid profiles of seized cannabis and cannabis-based medicines – Identification of potential distinguishing markers

2021

As the frequency of cannabis-based therapy increases, the ability to distinguish intake of cannabis-based medicines from recreational cannabis use becomes desirable. Minor cannabinoids have been suggested to indicate recreational cannabis use in biological matrices but are unreliable when presumably also present in directly plantderived medicines. Thus, for therapeutics such as medical cannabis, Sativex® and Dronabinol, a more thorough investigation of cannabinoid profiles is required to identify possible distinguishing markers. In this study, 16 phytocannabinoids were quantified in samples of seized and medical cannabis, Sativex® and Dronabinol from two different manufacturers, using a val…

Cannabigerolmedicine.medical_treatmentMedical MarijuanaTetrahydrocannabivarinMass SpectrometryCannabicyclolPathology and Forensic MedicineCannabichromenechemistry.chemical_compoundmedicineCannabidiolHumansDronabinolPrincipal Component AnalysisbiologyTraditional medicineCannabinoidsbusiness.industrybiology.organism_classificationDrug CombinationschemistryCannabinolCannabinoidCannabisDronabinolbusinessLawChromatography Liquidmedicine.drugForensic Science International
researchProduct